乳房假体植入后溢乳/乳囊肿的系统综述
该系统综述检索了Pubmed、Embase和Google Scholar,纳入19篇文章共38例乳房假体植入后出现溢乳或乳囊肿的女性。平均发病时间61天,多数在3个月内出现症状;治疗包括观察、药物和手术,平均22.6天缓解,但样本量小难以定论。
要点
- 乳房假体植入后溢乳/乳囊肿多在3个月内出现,平均61天。
- 乳晕周围切口(48%)和腺体下植入(57%)似为可能危险因素。
- 口服避孕药(42%)和近期哺乳(<1年)可能增加风险。
核心结论
- 样本量太小无法得出确定性结论,但弱提示乳晕周围切口、腺体下植入、既往激素避孕、妊娠及近期哺乳(<1年)可能是溢乳/乳囊肿的危险因素。
- 症状多在3个月内出现。
- 联合治疗(抗生素、多巴胺激动剂、手术引流及假体取出)反应最快(2天),雌激素药物获益甚微。
研究设计与样本
- 系统综述,2019年7月检索Pubmed、Embase和Google Scholar。
- 纳入19篇文章(17篇病例报告/系列和2篇回顾性病历回顾),共38例女性。
主要发现
- 平均年龄28岁,42%口服避孕药,四分之一未产。
- 最常见切口为乳晕周围(48%),其次腋窝(24%)。
- 最常见假体位置为腺体下(57%),其次胸肌下(37%)。
- 平均症状出现时间61天(范围3-912天),但仅3例在植入后超过1个月出现。
关键数值与推荐
- 管理策略包括观察、抗生素、多巴胺激动剂、白三烯受体拮抗剂、雌激素药物、手术冲洗和假体取出(8例)。
- 平均症状缓解时间22.6天。
临床怎么用
- 对乳房假体植入后出现溢乳或乳囊肿者,应评估激素避孕史、妊娠及哺乳史。
- 症状多在术后3个月内出现,需警惕乳晕周围切口及腺体下植入者。
- 高催乳素血症并非必备,仅62%存在。
- 治疗可先观察或药物,必要时手术引流或假体取出;雌激素药物似无益。
局限性
- 样本量小(38例),无法得出确定性结论。
- 纳入研究多为病例报告/系列,证据等级低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To review cases of galactorrhea and galactocele postbreast augmentation, determine possible risk factors and consider management strategies of this rare complication. METHODS: A systematic literature review was conducted in July 2019 searching Pubmed, Embase, and Google Scholar. RESULTS: The searches revealed 19 articles (17 case reports/series and 2 retrospective chart reviews) collectively comprising 38 women. The average age was 28 years, 42% were on oral contraceptives, whereas a quarter were nulliparous. The most common incision was periareolar (48%) followed by transaxillary (24%). The most common implant location was subglandular (57%) followed by subpectoral (37%). The average time to symptom onset was 61 days (range, 3-912 days) but only 3 cases presented more than a month after implant insertion. Twenty-one patients had galactorrhea, 7 had galactocele, whereas 10 women had both. Bilateral symptoms were present in 72% of cases, whereas hyperprolactinemia was present in only 62%. Management strategies included simple surveillance, antibiotics, dopamine agonists, leukotriene receptor antagonists, estrogenic agents, surgical washout, and implant removal (8 patients). The mean time to symptom resolution was 22.6 days. CONCLUSIONS: The numbers are too small for definitive conclusions but there is a weak suggestion that periareolar incisions, subglandular implants, prior hormonal contraceptive use, gravidity, and recent history of breastfeeding (<1 year) may be risk factors for galactorrhea/galactocele. Symptom onset is usually within 3 months. Treatments providing the fastest response (2 days) comprised of a composite approach (antibiotics, dopamine agonist, surgical drainage, and implant removal), whereas the use of estrogenic medications appeared to confer little benefit.
引用
- Sharma SC, Basu NN. Galactorrhea/Galactocele After Breast Augmentation: A Systematic Review. Ann Plast Surg. 2021. PMID: 32079808. doi:10.1097/SAP.0000000000002290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。